##  [Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD](/us-en/news/media-releases/novartis-announces-fda-filing-acceptance-and-priority-review-brolucizumab-rth258-patients-wet-amd-0 "Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD") 

  Apr 15, 2019